Metagenomi Therapeutics, Inc. reported a net loss of $23.1 million for the first quarter of 2026, a decrease from the $25.0 million loss recorded in the same period of the previous year. The company's collaboration revenue fell to $1.2 million, down from $4.1 million in the first quarter of 2025, primarily due to a significant reduction in revenue from its collaboration with Ionis Pharmaceuticals. Operating expenses also decreased to $25.8 million from $31.9 million year-over-year, driven by lower research and development costs, which dropped to $19.3 million from $25.1 million.
The company experienced a notable change in its financial position, with total assets decreasing to $197.0 million as of March 31, 2026, from $221.1 million at the end of 2025. Cash and cash equivalents were reported at $25.3 million, down from $41.7 million, while available-for-sale marketable securities also saw a decline. The accumulated deficit increased to $333.9 million, reflecting the ongoing challenges in achieving profitability.
Strategically, Metagenomi has focused on advancing its lead programs, particularly in gene-editing technologies, and has undergone a corporate name change to emphasize its commitment to therapeutic development. The company is preparing for a global clinical program for its lead candidate, MGX-001, aimed at treating hemophilia A, with an investigational new drug application expected to be submitted in late 2026. Additionally, the company has entered into a collaboration agreement with Ionis, which is currently in the lead optimization phase for four disease targets.
Operationally, Metagenomi's employee headcount and engagement metrics have been stable, with no significant changes reported in staffing levels. The company continues to monitor macroeconomic conditions that could impact its operations, including inflation and geopolitical tensions. Looking ahead, Metagenomi anticipates that its existing cash and marketable securities will be sufficient to fund operations for at least the next 12 months, although it acknowledges the need for additional capital to support ongoing research and development activities. The company remains committed to leveraging its proprietary technologies to develop curative genetic medicines while navigating the complexities of the biotechnology landscape.
About Metagenomi, Inc.
Metagenomi, Inc. is a genetic medicines company specializing in genome editing technologies. Using proprietary metagenomics, AI, and advanced molecular tools, it develops precise, durable gene editing systems for treating genetic and protein deficiency diseases. Its portfolio includes in vivo therapies for hemophilia A, secreted protein disorders, and collaborations targeting cardiometabolic conditions, aiming to deliver potentially curative, one-time treatments across multiple organs and disease areas.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.